Trial Profile
A phase Ia/Ib study of doxorubicin transferrin conjugate [TRF-DOX] in patients with lung cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2015
Price :
$35
*
At a glance
- Drugs Doxorubicin conjugate (Primary)
- Indications Lung cancer
- Focus Adverse reactions
- 17 Apr 2015 New trial record